Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia

Transfusion and Apheresis Science

Volumn 30, Issue 3, 2004, Pages 233-243

  Mabuchi, Hiroshi ^a   Higashikata, Toshinori ^a   Kawashiri, Masa Aki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Beyond cardiovascular diseases; Coronary heart disease; Familial hypercholesterolemia (FH); LDL apheresis

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; COLESTILAN; CORTICOSTEROID; DEXTRAN SULFATE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; POLYACRYLIC ACID; PRAVASTATIN; PREDNISOLONE; PROBUCOL; RESIN; SIMVASTATIN; STEROID;

APHERESIS; ARTERY LESION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DIABETES MELLITUS; EMBOLISM; FAMILIAL HYPERCHOLESTEROLEMIA; HEARING LOSS; HEPATITIS C; HUMAN; IMMUNOADSORPTION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; REMISSION; RISK FACTOR; SCLERODERMA;

ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL;

EID: 2542533778     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2004.01.006     Document Type: Conference Paper

References (72)

1. Stamler J., Wentworth D., Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?. Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 256:1986;2823-2828
2. Mabuchi H., Koizumi J., Shimizu M., Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation. 79:1989;225-232
3. Thompson G.R., Lowenthal R., Myant N.B. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1:1975;1208-1211
4. Lupien P.J., Moorjani S., Awad J. A new approach to the management of familial hypercholesterolaemia: Removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet. 1:1976;1261-1265
5. Mabuchi H., Michishita I., Sakai T., Sakai Y., Watanabe A., Wakasugi T., et al. Treatment of homozygous patients with familial hypercholesterolemia by double-filtration plasmapheresis. Atherosclerosis. 61:1986;135-140
6. Mabuchi H., Michishita I., Takeda M., Fujita H., Koizumi J., Takeda R., et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis. 68:1987;19-25
7. Thompson G.R. LDL apheresis. Atherosclerosis. 167:2003;1-13
8. Bambauer R., Schiel R., Latza R. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies. Ther. Apher. 4:2000;213-217
9. Bambauer R., Schiel R., Latza R. Current topics on low-density lipoprotein apheresis. Ther. Apher. 5:2001;293-300
10. Bambauer R., Schiel R., Latza R. Low-density lipoprotein apheresis: an overview. Ther. Apher. Dial. 7:2003;382-390
11. Ritter M.M., Parhofer K.G. Extracorporal low-density lipoprotein elimination by immunoadsorption. Ther. Apher. Dial. 7:2003;370-372
12. Bosch T., Schmidt B., Blumenstein M., Gurland H.J. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif. Organs. 17:1993;640-652
13. Bosch T., Schmidt B., Kleophas W., Gillen C., Otto V., Passlick-Deetjen J., et al. LDL hemoperfusion - a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. Artif. Organs. 21:1997;977-982
14. Bosch T., Lennertz A., Schmidt B., Fink E., Keller C., Toepfer M., et al. DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selectivity of direct adsorption of lipoproteins from whole blood. Artif. Organs. 24:2000;81-90
15. Bosch T., Lennertz A., Schenzle D., Drager J. Direct adsorption of lipoproteins (DALI) study group. Direct adsorption of low-density lipoprotein and lipoprotein (a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis. J. Clin. Apheresis. 17:2002;161-169
16. Bosch T., Keller C. Clinical effects of direct adsorption of lipoprotein apheresis: beyond cholesterol reduction. Ther. Apher. Dial. 7:2003;341-344
17. Mabuchi H., Fujita H., Michishita I., Takeda M., Kajinami K., Koizumi J., et al. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis. Atherosclerosis. 72:1988;183-188
18. Yamamoto A., Harada-Shiba M., Kawaguchi A., Oi K., Kubo H., Sakai S., et al. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis. 153:2000;89-98
19. Goldammer A., Wiltschnig S., Heinz G., Jansen M., Stulnig T., Horl W.H., et al. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia. Metabolism. 51:2002;976-980
20. Otto C., Geiss H.C., Donner M.G., Parhofer K.G., Schwandt P. Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis. Ther. Apher. 4:2000;244-248
21. Schmaldienst S., Banyai S., Stulnig T.M., Heinz G., Jansen M., Horl W.H., et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis. 151:2000;493-499
22. Hoffmann U., Derfler K., Haas M., Stadler A., Brady T.J., Kostner K. Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography. Am. J. Cardiol. 91:2003;461-464
23. Banyai S., Banyai M., Falger J., Jansen M., Alt E., Derfler K., et al. Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. Atherosclerosis. 159:2001;513-519
24. Gagne C., Gaudet D., Bruckert E. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 105:2002;2469-2475
25. Fukazawa Y., Kurata K., Machida H. In one patient treated by hemodyalysis, LDL-apheresis was replaced by the combination drug therapy of colestimide and atorvastatin. Prog. Med. 21:2001;1337-1340. (Japanese)
26. Kajinami K., Mabuchi H. Therapeutic effects of LDL apheresis in the prevention of atherosclerosis. Curr. Opin. Lipidol. 10:1999;401-406
27. Moriarty P.M., Gibson C.A. Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses. Curr. Atheroscler. Rep. 3:2001;156-162
28. Yamamoto A., Harada-Shiba M., Kawaguchi A., Tsushima M. Apheresis technology for prevention and regression of atherosclerosis. Ther. Apher. 5:2001;221-225
29. Tasaki H. Low-density lipoprotein apheresis in the prevention of recurrent coronary heart disease: a review. Ther. Apher. Dial. 7:2003;408-412
30. Mabuchi H., Koizumi J., Shimizu M., Kajinami K., Miyamoto S., Ueda K., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol. 82:1998;1489-1495
31. Matsuzaki M., Hiramori K., Imaizumi T., Kitabatake A., Hishida H., Nomura M., et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART. J. Am. Coll. Cardiol. 40:2002;220-227
32. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82
33. Schuff-Werner P., Gohlke H., Bartmann U., Baggio G., Corti M.C., Dinsenbacher A., et al. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur. J. Clin. Invest. 24:1994;724-732
34. Rubba P., Faccenda F., Di Somma S., Gnasso A., Scarpato N., Iannuzzi A., et al. Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia. Stroke. 24:1993;1154-1161
35. Koga N., Watanabe K., Kurashige Y., Sato T., Hiroki T. Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. J. Int. Med. 246:1999;35-43
36. Muso E., Mune M., Fujii Y., Imai E., Ueda N., Hatta K., et al. Kansai FGS LDL Apheresis Treatment (K-FLAT) Study Group. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron. 89:2001;408-415
37. Suckfull M. Hearing Loss Study Group. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet. 360:2002;1811-1817
38. Tsunoda S., Daimon S., Miyazaki R., Fujii H., Inazu A., Mabuchi H. LDL apheresis as intensive lipid-lowering therapy for cholesterol embolism. Nephrol. Dial. Transplant. 14:1999;1041-1042
39. Hasegawa M., Sugiyama S. Apheresis in the treatment of cholesterol embolic disease. Ther. Apher. Dial. 7:2003;435-436
40. Koga N. Beneficial effect of aggressive low-density lipoprotein apheresis in a familial hypercholesterolemic patient with severe diabetic scleredema. Ther. Apher. 5:2001;506-512
41. Schettler V., Monazahian M., Wieland E., Thomssen R., Muller G.A. Effect of heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) apheresis on hepatitis C plasma virus load. Ther. Apher. 5:2001;384-386
42. Moriarty P.M., Gibson C.A., Shih J., Matias M.S. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis. 158:2001;495-498
43. Kojima S., Shida M., Yokoyama H. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther. Apher. Dial. 7:2003;431-434
44. Kobayashi J., Katsube S., Shimoda M., Furuhashi K., Kitano S., Masuda M., et al. Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. Clin. Chim. Acta. 321:2002;107-112
45. Empen K., Otto C., Brodl U.C., Parhofer K.G. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J. Clin. Apheresis. 17:2002;38-43
46. Richter V., Rassoul F., Reuter W., Purcz T., Julius U., Glaser V., et al. Effect of extracorporeal low-density lipoprotein elimination on circulating cell adhesion molecules in patients with hypercholesterolemia. Am. J. Cardiol. 87:2001;1111-1113
47. Yamane S., Matsugane T., Motohashi K., Nobuto T., Azuma N., Nishide T., et al. Double filtration plasmapheresis maintains normal adhesion molecule levels. Ther. Apher. 2:1998;224-227
48. Motohashi K., Yamane S. The effect of apheresis on adhesion molecules. Ther. Apher. Dial. 7:2003;425-430
49. Kojima S., Shida M., Tanaka K., Takano H., Yokoyama H., Kuramochi M. Acute changes in plasma levels of hepatocyte growth factor during low-density lipoprotein apheresis. Ther. Apher. 5:2001;2-6
50. Pfohl M., Naoumova R.P., Klass C., Knisel W., Jakober B., Risler T., Thompson G.R. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res. 35:1994;1946-1955
51. Palcoux J.B., Meyer M., Jouanel P., Vanlieferinghen P., Malpuech G. Comparison of different treatment regimens ina case of homozygous familial hypercholesterolemia. Ther. Apher. 6:2002;136-139
52. Suzaki K., Kobori S., Ueno S., Uehara M., Kayashima T., Takeda H., et al. Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis. 80:1990;181-189
53. Hattori M., Ito K., Kawaguchi H., Tanaka T., Kubota R., Khono M. Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol. 7:1993;196-198
54. Muso E., Yashiro M., Matsushima M., Yoshida H., Sawanishi K., Sasayama S. Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial Transplant. 9:1994;257-264
55. Yokoyama K., Sakai S., Yamaguchi Y., Suzuki Y., Hinoshita F., Hara S., et al. Complete remission of the nephrotic syndrome due to focal glomerular sclerosis achieved with low density lipoprotein adsorption alone. Nephron. 72:1996;318-320
56. Iwahori T., Yoshida M., Sugiura M., Ioya N., Kawaguchi M. Excellent antiproteinuric effect by LDL apheresis in a case with severe renal dysfunction due to focal segmental glomerulosclerosis. Nippon Jinzo Gakkai Shi. 38:1996;91-97. (Japanese)
57. Okada T., Takahashi H., Ogura M., Nakao T., Shimizu T. Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment. Nippon Jinzo Gakkai Shi. 38:1996;46-51. (Japanese)
58. Faucher C., Albeit C., Beaufils H., Jouanneau C., Dupouet L. Remission of a refractory nephrotic syndrome after low-density lipoprotein apheresis based on dextrane sulphate adsorption. Nephrol Dial Transplant. 12:1997;1037-1039
59. Yokoyama K., Sakai S., Sigematsu T., Takemoto F., Hara S., Yamada A., et al. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol. 50:1998;1-7
60. Brunton C., Varghese Z., Moorhead J.F. Lipopheresis in the nephrotic syndrome. Kidney Int Suppl. 71:1999;S6-S9
61. Stenvinkel P., Alvestrand A., Angelin B., Eriksson M. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Eur J Clin Invest. 30:2000;866-870
62. Ideura T., Hora K., Kaneko Y., Yamazaki T., Tokunaga S., Shigematsu H., Kiyosawa K. Effect of low-density lipoprotein-apheresis on nephrotic syndrome due to membranous nephropathy in renal allograft: a case report. Transplant Proc. 32:2000;223-226
63. Daimon S., Saga T., Nakayama M., Nomura Y., Chikaki H., Dan K., Koni I. Dextran sulphate cellulose columns for the treatment of nephrotic syndrome due to inactive lupus nephritis. Nephrol Dial Transplant. 15:2000;235-238
64. Takaki A., Nakatsuka A., Satou G., Iwata Y., Ikeda H., Fukushima M. A case of focal segmental glomerulosclerosis (FSGS) complicated with chronic hepatitis B and treated with steroid and LDL apheresis. Nippon Jinzo Gakkai Shi. 44:2002;806-812. (Japanese)
65. Kamijo Y., Kaneko Y., Ichikawa T., Kobayashi N., Koyama T., Kakegawa T., et al. A case of nephrotic syndrome due to lupus nephritis which was controlled with low-density lipoprotein apheresis. Ther Apher. 6:2002;459-462
66. Yoshizawa T., Suzuki T., Kanmatsuse K. Usefulness of LDL-apheresis for treatment of steroid-resistant nephrotic syndrome. Nippon Jinzo Gakkai Shi. 45:2003;25-31. (Japanese)
67. Geusau A., Schmaldienst S., Derfler K., Papke O., Abraham K. Severe 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: kinetics and trials to enhance elimination in two patients. Arch Toxicol. 76:2002;316-325
68. Kobayashi S., Moriya H., Negishi K., Maesato K., Ohtake T. LDL-apheresis up-regulates VEGF and IGF-I in patients with ischemic limb. J Clin Apheresis. 18:2003;115-119
69. Schettler V., Krontal J., Scheel A., Wieland E. No acute impact of lipid apheresis treatment on free radical scavenging enzyme gene expression in white blood cells. Eur J Clin Invest. 33:2003;134-140
70. Stefanutti C., Di Giaeomo S., Vivenzio A., Isacchi G.C., Masella R., Caprari P., et al. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Clin Sci (Lond). 100:2001;191-198
71. Bosch T., Wendler T., Jaeger B.R., Samtleben W. Improvement of hemorheology by DALI apheresis: acute effects on plasma viscosity and erythrocyte aggregation in hypercholesterolemic patients. Ther Apher. 5:2001;372-376
72. Nakamura T., Matsuda T., Suzuki Y., Ueda Y., Koide H. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ASAIO J. 49:2003;430-434